Khoo S K, Hurst T, Webb M J, Dickie G, Kearsley J, Parsons P G, Mackay E V
University of Queensland Department of Obstetrics and Gynaecology, Brisbane.
Aust N Z J Obstet Gynaecol. 1988 Nov;28(4):313-7. doi: 10.1111/j.1479-828x.1988.tb01689.x.
The in vitro response to cis-diamminodichloroplatinum (cisplatin) in primary culture of tumour samples obtained at surgery was studied in 61 patients with Stage III ovarian cancer who were also treated with cisplatin. The drug-induced inhibitory effect on cell proliferation (measured by 3H-thymidine incorporation) and metabolism (by 3H-uridine incorporation) was assessed over a 3-hour incubation. At greater than or equal to 20% level of inhibition, the true prediction rate of survival by the proliferative assay was 72% among those with 'sensitive' tumours and of mortality was 66% among those with 'resistant' tumours; at greater than or equal to 50% level of inhibition, the prediction rate of survival by the proliferative assay increased to 88% but that of mortality decreased to 58%. The results with the metabolic assay were comparatively lower at all levels. When the amount of residual disease was taken into the determination of mortality rate, significant differences were found between 'sensitive' and 'resistant' tumours as defined by the proliferative assay in patients with no/minimal disease. The pattern of survival differed significantly between 3 subgroups of tumours, as defined by their responses to cisplatin in the proliferative and metabolic assays -- the best survival was obtained in patients whose tumours were 'sensitive' in both assays.
对61例III期卵巢癌患者进行了研究，这些患者在手术时获取肿瘤样本进行原代培养，并接受顺铂治疗，以研究肿瘤样本原代培养物对顺二氨二氯铂（顺铂）的体外反应。在3小时的孵育过程中，评估了药物对细胞增殖（通过3H-胸腺嘧啶核苷掺入法测量）和代谢（通过3H-尿苷掺入法测量）的抑制作用。在抑制水平大于或等于20%时，增殖试验对“敏感”肿瘤患者生存的真实预测率为72%，对“耐药”肿瘤患者死亡的预测率为66%；在抑制水平大于或等于50%时，增殖试验对生存的预测率升至88%，但对死亡的预测率降至58%。代谢试验在所有水平的结果相对较低。当将残留疾病量纳入死亡率的测定时，在无/少量疾病的患者中，根据增殖试验定义的“敏感”和“耐药”肿瘤之间存在显著差异。根据肿瘤在增殖和代谢试验中对顺铂的反应所定义的3个肿瘤亚组之间的生存模式存在显著差异——在两种试验中肿瘤均“敏感”的患者生存情况最佳。
